COMMUNIQUÉS West-GlobeNewswire

-
Onconova Highlights Results from Phase 2 Trial of Oral Rigosertib In Combination with Azacitidine (Vidaza®) in Myelodysplastic Syndromes (MDS) at the 2018 ASH Annual Meeting
03/12/2018 -
Theratechnologies Appoints New Chief Commercial Officer
03/12/2018 -
Theratechnologies nomme un nouveau chef de l’exploitation commerciale
03/12/2018 -
Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting
03/12/2018 -
Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product
03/12/2018 -
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
03/12/2018 -
Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting
03/12/2018 -
OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
03/12/2018 -
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
03/12/2018 -
Advanced Accelerator Applications signs exclusive option and license agreement with FUJIFILM Toyama Chemical to develop and commercialize radiolabeled FF-10158 for oncology indications
03/12/2018 -
Genmab to Hold R&D Update and 2018 ASH Data Review Meeting
03/12/2018 -
GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis
03/12/2018 -
GENFIT : Lancement aux États-Unis d'une étude de Phase 2 initiée par un investigateur, évaluant nitazoxanide chez des patients avec fibrose NASH
03/12/2018 -
Press release: Terveystalo to become a shareholder in startup company Etsimo Healthcare - harnessing AI to assist the customer and the healthcare professional
03/12/2018 -
Rule 2.9 Announcement
03/12/2018 -
Total voting rights
03/12/2018 -
Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1
03/12/2018 -
Helsinn and Mundipharma China Pharmaceutical Announce Approval of ALOXI® IV by the National Medical Products Administration (NMPA)
03/12/2018 -
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
03/12/2018
Pages